Israeli study: 2nd vaccine booster significantly lowers COVID death rate
Send a link to a friend
[March 28, 2022]
JERUSALEM (Reuters) - Senior
citizens who received a second booster of the Pfizer–BioNTech COVID-19
vaccination had a 78% lower mortality rate from the disease than those
who got one only, a study from Israel showed on Sunday.
The country's largest healthcare provider, Clalit Health Services, said
the 40-day study included more than half a million people aged 60 to
100.
Some 58% of participants had received a second booster - or two shots in
addition to the basic two-shot regimen. The remainder had received only
one booster. Researchers recorded 92 deaths among the first group and
232 deaths among the second, smaller group.
"The main conclusion is that the second booster is lifesaving," said
Ronen Arbel, Health Outcomes Researcher at Clalit and Sapir College.
![](http://archives.lincolndailynews.com/2022/Mar/28/images/ads/current/ldn_sda_062409.png)
[to top of second column]
|
![](../images/032822PIX/health75.jpg)
89-year-old Yodit Ben Ari receives a fourth dose of the coronavirus
disease (COVID-19) vaccine following a vaccination party after
Israel approved a second booster shot for the immunocompromised,
people over 60 years and medical staff in a retirement home in
Netanya, Israel January 5, 2022. REUTERS/Ammar Awad
![](http://archives.lincolndailynews.com/2022/Mar/28/images/ads/current/lincolnag_daily_sda_SFARM_2022.png)
The report was issued as a preprint
and has not been peer-reviewed. The research excluded people who
received rival Moderna's vaccine and those who had taken oral anti-COVID
therapy.
Israeli health officials have put out a number of studies on vaccine
efficacy throughout the pandemic that have impacted policymaking in
other countries.
(Reporting by Ari Rabinovitch; Editing by Raissa Kasolowsky)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |